A lot of money and energy is being invested in improving upon and supplementing the analysis conducted by radiologists of medical images. The expectation is that computers will offer a more precise and consistent inspection than practiced human eyes that will be applied to ever more sophisticated, timely and complex medical images.
GE Healthcare, which has been on an expansion binge, intends to double its manufacturing capacity for medical imaging contrast media at its plant in Carrigtwohill, Cork, Ireland, with a $40 million expansion.
GE Healthcare is launching its Health Cloud--an effort to make images available to healthcare providers across multiple settings and to encourage remote analysis of them. It currently includes four cloud-based apps and was disclosed as part of the ongoing Radiological Society of North America meeting in Chicago, IL.
Imaging company Dilon Diagnostics has landed a partnership to distribute a molecular breast imaging system from GE Healthcare in select, undisclosed global geographies. The offering is intended to complement Dilon's own molecular imaging offerings.
The effective diagnosis and treatment of cancer has remained a largely First World problem so far. But someday, perhaps sooner rather than later, that's expected to no longer be the case. A coalition has created a global initiative to improve access to some of the most underserved populations in sub-Saharan Africa and Haiti.
GE Healthcare will work with Oregon Health & Science University to develop collaborative research programs in cardiovascular medicine, imaging and big data research. They expect to address essential questions about biology and medicine through the combination of the clinical expertise of OHSU and the technological facility of GE Healthcare.
The race is on to develop U.S. sources for a material necessary to create the most widely used radioisotope in medical diagnostic imaging. Now GE Healthcare and startup Shine Technologies have disclosed that they have successfully used GE's existing tech to create the common medical radioisotope technetium-99m (Tc‑99m) from molybdenum-99 (Mo-99) produced by Shine.
Call it a biopharma plant in a box--62 boxes actually. That is how many containers were shipped from a GE production facility to China to build GE's first prefab biologics plant for JHL Biotech, a company founded by U.S. biotech veterans working on biosimilars.
Oncology genomics player NeoGenomics is slated to buy GE cancer diagnostic unit Clarient Diagnostic Services in a cash and stock deal worth about $300 million. That's an impressive feat given that NeoGenomics' market cap was less than $350 million prior to the deal announcement.
GE Healthcare has staked a major claim in a field that's not well tended--the development of affordable medical technologies to improve health outcomes in the emerging markets. It's creating a devoted business called Sustainable Healthcare Solutions out of a combination of its operations in India, South Asia, Africa and Southeast Asia dedicated to serving 70 markets--and investing $300 million to back the effort.